JP2020519660A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519660A5
JP2020519660A5 JP2019563125A JP2019563125A JP2020519660A5 JP 2020519660 A5 JP2020519660 A5 JP 2020519660A5 JP 2019563125 A JP2019563125 A JP 2019563125A JP 2019563125 A JP2019563125 A JP 2019563125A JP 2020519660 A5 JP2020519660 A5 JP 2020519660A5
Authority
JP
Japan
Prior art keywords
inhibitor
cancer
item
combinations
delta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019563125A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519660A (ja
JP7405408B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/032755 external-priority patent/WO2018213302A1/en
Publication of JP2020519660A publication Critical patent/JP2020519660A/ja
Publication of JP2020519660A5 publication Critical patent/JP2020519660A5/ja
Priority to JP2022160828A priority Critical patent/JP2022176316A/ja
Application granted granted Critical
Publication of JP7405408B2 publication Critical patent/JP7405408B2/ja
Priority to JP2025100020A priority patent/JP2025123379A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019563125A 2017-05-16 2018-05-15 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法 Active JP7405408B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022160828A JP2022176316A (ja) 2017-05-16 2022-10-05 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法
JP2025100020A JP2025123379A (ja) 2017-05-16 2025-06-16 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762506995P 2017-05-16 2017-05-16
US62/506,995 2017-05-16
PCT/US2018/032755 WO2018213302A1 (en) 2017-05-16 2018-05-15 Compositions and methods for treating cancer with atypical braf mutations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022160828A Division JP2022176316A (ja) 2017-05-16 2022-10-05 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2020519660A JP2020519660A (ja) 2020-07-02
JP2020519660A5 true JP2020519660A5 (cg-RX-API-DMAC10.html) 2021-07-26
JP7405408B2 JP7405408B2 (ja) 2023-12-26

Family

ID=64274828

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019563125A Active JP7405408B2 (ja) 2017-05-16 2018-05-15 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法
JP2022160828A Withdrawn JP2022176316A (ja) 2017-05-16 2022-10-05 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法
JP2025100020A Pending JP2025123379A (ja) 2017-05-16 2025-06-16 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022160828A Withdrawn JP2022176316A (ja) 2017-05-16 2022-10-05 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法
JP2025100020A Pending JP2025123379A (ja) 2017-05-16 2025-06-16 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法

Country Status (8)

Country Link
US (1) US12582635B2 (cg-RX-API-DMAC10.html)
EP (1) EP3624896B1 (cg-RX-API-DMAC10.html)
JP (3) JP7405408B2 (cg-RX-API-DMAC10.html)
CN (2) CN110799245B (cg-RX-API-DMAC10.html)
AU (2) AU2018269982B2 (cg-RX-API-DMAC10.html)
CA (1) CA3063614A1 (cg-RX-API-DMAC10.html)
MX (1) MX2019013634A (cg-RX-API-DMAC10.html)
WO (1) WO2018213302A1 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN109771436A (zh) * 2019-03-06 2019-05-21 康赋葆(深圳)生物医药科技有限公司 四氢姜黄素与卡培他滨联合治疗大肠癌的应用
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
JP7234418B2 (ja) * 2019-05-16 2023-03-07 イーライ リリー アンド カンパニー Ｂｒａｆｖ６００ｅ大腸癌の治療に使用するためのｅｒｋ１／２阻害剤と、ｂｒａｆ阻害剤およびｅｇｆｒ阻害剤との三重組み合わせ
PH12021553058A1 (en) 2019-06-06 2022-07-25 Hutchison Medipharma Ltd Tricyclic compounds and their use
GB201913124D0 (en) * 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913123D0 (en) * 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913121D0 (en) * 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
CN110538316B (zh) * 2019-10-17 2021-10-15 滨州医学院 5-fu和胰高血糖素联合用于制备治疗结直肠癌的药物的用途和药物组合物
CN115151533B (zh) 2020-01-10 2025-08-08 医疗免疫工程公司 Mek抑制剂及其治疗用途
TW202140029A (zh) * 2020-02-18 2021-11-01 瑞士商諾華公司 用於治療ｂｒａｆ突變型ｎｓｃｌｃ的包含ｒａｆ抑制劑之治療組合
CA3175127A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2022179568A1 (en) * 2021-02-25 2022-09-01 Westlake Therapeutics (Hangzhou) Co., Limited Neoantigenic peptide and its use for treating braf gene mutation related diseases
CN117940130A (zh) * 2021-03-09 2024-04-26 基因泰克公司 用于脑癌治疗的贝伐拉非尼
EP4378478A4 (en) * 2021-07-27 2025-11-12 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
US20240374569A1 (en) * 2021-09-22 2024-11-14 Henry Ford Health System Hdac3 inhibitors for the treatment of langerhans cell histiocytosis and langerhans cell sarcoma
CN116570599B (zh) * 2023-07-04 2023-10-20 四川大学华西医院 Vs6766联合ly3009120的应用及药物组合物
CN121243179B (zh) * 2025-12-05 2026-02-24 山东大学 盐酸帕唑帕尼在制备卵巢功能保护药物方面的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009077712A (ja) * 2007-09-11 2009-04-16 F Hoffmann La Roche Ag Ｂ−Ｒａｆキナーゼ阻害剤に対する感受性についての診断試験
UA116544C2 (uk) 2012-08-09 2018-04-10 Селджин Корпорейшн Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
WO2014028461A2 (en) 2012-08-13 2014-02-20 The Rockefeller University Treatment and diagnosis of melanoma
US9913844B2 (en) * 2013-03-21 2018-03-13 Novartis Ag Combination therapy
CA2908508C (en) 2013-03-29 2023-09-19 Biomed Valley Discoveries, Inc. C. novyi for the treatment of solid tumors in humans
TWI839690B (zh) * 2013-07-12 2024-04-21 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合的用途
AU2014368925A1 (en) * 2013-12-20 2016-07-21 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of MEK type I and ERK inhibitors
WO2015095835A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods of modulating radioiodine uptake for the treatment of radioiodine-refractory cancers
WO2015095842A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
US11013743B2 (en) * 2013-12-20 2021-05-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
AU2014368912B2 (en) * 2013-12-20 2020-04-30 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of type 2 MEK and ERK inhibitors
BR112016014481B1 (pt) 2013-12-20 2022-11-08 Biomed Valley Discoveries, Inc Uso de uma composição farmacêutica, método in vitro para efetuar a morte de células cancerosas, e kit
EP3082957B1 (en) * 2013-12-20 2022-04-06 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors
CA2953732C (en) * 2014-07-14 2023-09-26 Universitat Zurich Prorektorat Mnw Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor
WO2016025650A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
CN107922387B (zh) * 2015-06-15 2024-11-22 阿沙纳生物科学公司 Erk1与erk2的杂环抑制剂及其在癌症治疗中的应用
US20190071668A1 (en) 2015-07-08 2019-03-07 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of cancer using slncr isoforms

Similar Documents

Publication Publication Date Title
JP7405408B2 (ja) 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法
US11679112B2 (en) Cancer treatments using combinations of CDK and ERK inhibitors
Herrera et al. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
Bianco et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa)
Saad et al. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer
Dong et al. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma
JP7788114B2 (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
JP2017502017A5 (cg-RX-API-DMAC10.html)
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
JP2017500320A5 (cg-RX-API-DMAC10.html)
CN101743013A (zh) 使用整联蛋白配体治疗癌的特异疗法和药物
WO2015095831A1 (en) Cancer treatments using combinations of mtor and erk inhibitors
Rocchi et al. The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets
Miller et al. Combination treatment options for castration-resistant prostate cancer
Kochar et al. Contemporary updates on clinical trials of antiangiogenic agents in the treatment of glioblastoma multiforme
WO2014160967A2 (en) C. novyi for the treatment of solid tumors in non-human animals
Higano New treatment options for patients with metastatic castration-resistant prostate cancer
CA3118690A1 (en) Use of tivozanib to treat subjects with refractory cancer
RU2024101803A (ru) Композиции и способы для лечения злокачественной опухоли с атипичными мутациями braf
Sonis et al. Rationale for effective interventions to mitigate oral mucositis in patients being treated with TROP-2-directed antibody-drug conjugates with a topoisomerase inhibitor payload
JP2012509287A (ja) 癌を治療するためのインテグリンリガンドを用いる新規療法および医薬
US20220096436A1 (en) Combination product for the treatment of cancer
HK40086947A (en) Compositions and methods for treating cancer with atypical braf mutations
US20090062246A1 (en) Therapeutic treatment-014
Jhaveri et al. Targeting Tumor Angiogenesis in Combination with Endocrine Therapy in Patients with Hormone-Receptor Positive Metastatic Breast Cancer.